• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » AliveCor earns another FDA nod for AI-powered 12-lead ECG tech

AliveCor earns another FDA nod for AI-powered 12-lead ECG tech

January 13, 2026 By Sean Whooley

Kardia 12L ECG System (1)
The Kardia 12L. [Image courtesy of AliveCor]
AliveCor announced today that it received FDA clearance for the next generation of its AI technology for the Kardia 12L ECG system.

KAI 12L, the AI powering the Kardia 12L ECG system, can now detect five additional cardiac determinations with the clearance. That brings the total for the 12-lead electrocardiogram (ECG) technology to 39 cleared determinations.

Mountain View, California–based AliveCor develops the first-of-its-kind handheld ECG system to detect various cardiac conditions. It leverages the KAI 12L deep neural network machine learning AI model, an advanced AI software algorithm trained on more than 1 million recorded ECGs. Its nearly 40 determinations include myocardial infarction (heart attack) and the most common types of cardiac ischemia.

The battery-operated, pocket-sized system weighs just 0.3 lbs and uses just one cable with a reduced lead set. It features just five electrodes, halving the standard 10 electrodes, used to acquire eight high-quality diagnostic bandwidth leads. The company says this simplifies and speeds up the process of obtaining a reading, enabling physicians in rapid disease detection.

AliveCor won FDA clearance for the 12-lead ECG system midway through 2024. About a year ago, the company also picked up a significant reimbursement win for the technology.

The company said its latest FDA nod further enhances the diagnostic breadth of the AI-powered ECG, adding three additional rhythm modifiers to its capabilities. Those include short PR interval (short PR), atrial bigeminy, and ventricular bigeminy. It also now offers two axis-related morphology determinations: left axis deviation (LAD) and right axis deviation (RAD).

“We are continuously expanding the diagnostic capabilities of our AI, and this latest clearance puts even more power into the hands of clinicians, delivering a high-fidelity 12-lead ECG, whose portable form can be deployed in any location, even in the most restricted or unconventional care settings,” said Priya Abani, CEO of AliveCor. “This milestone further solidifies AliveCor’s leadership in AI-powered cardiology as we continue to disrupt traditional care pathways and drive greater efficiency for healthcare providers.”

Filed Under: Artificial Intelligence (AI), Cardiovascular, Diagnostics, Digital Health, Featured, Food & Drug Administration (FDA), Health Technology, Machine Learning (ML), Patient Monitoring, Regulatory/Compliance, Software / IT Tagged With: AliveCor, FDA

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy